Evaluating the safety of a rotavirus vaccine: the REST of the story
Authors:
Open Access
- 28 March 2008
- journal article
- Published by SAGE Publications in Clinical Trials
- Vol. 5 (2) , 131-139
Abstract
The Rotavirus Efficacy and Safety Trial (REST) was a blinded, placebo-controlled study of the live pentavalent human-bovine vaccine, RotaTeq® (Merck & Co. Inc., West Point, PA). REST was noteworthy because its primary objective was to evaluate the safety of RotaTeq® with regard to intussusception, a rare intestinal illness that occurs with a background incidence of approximately 50 cases per 100 000 infant years. The study involved approximately 70 000 infants at over 500 study sites in 11 countries. The study demonstrated that the risk of intussusception was similar in vaccine and placebo recipients and that the vaccine prevented rotavirus gastroenteritis, ameliorated the severity of disease in those who had any disease, and substantially reduced rotavirus-associated hospitalizations and other health care contacts. This report provides an in-depth review of the background, statistical and regulatory considerations, and execution of REST. We describe the rationale and methods used for sample size, continuous safety monitoring, group sequential design, and detailed study execution. The results of the study have been reported elsewhere. The design and conduct of this study may serve as a useful model for planning other future large-scale clinical trials, especially those evaluating uncommon adverse events. Clinical Trials 2008; 5: 131—139. http:// ctj.sagepub.comKeywords
This publication has 22 references indexed in Scilit:
- Effects of the potency and composition of the multivalent human-bovine (WC3) reassortant rotavirus vaccine on efficacy, safety and immunogenicity in healthy infantsVaccine, 2006
- Safety and Efficacy of a Pentavalent Human–Bovine (WC3) Reassortant Rotavirus VaccineNew England Journal of Medicine, 2006
- Development of a Pentavalent Rotavirus Vaccine against Prevalent Serotypes of Rotavirus GastroenteritisThe Journal of Infectious Diseases, 2005
- Evaluating the Safety of New Vaccines: Summary of a WorkshopAmerican Journal of Public Health, 2005
- An Analysis of Rotavirus Vaccine Reports to the Vaccine Adverse Event Reporting System: More Than Intussusception Alone?Pediatrics, 2004
- INTUSSUSCEPTION AND ROTAVIRUS VACCINES: WHAT IS THE BACKGROUND RISK?The Pediatric Infectious Disease Journal, 2004
- Global Illness and Deaths Caused by Rotavirus Disease in ChildrenEmerging Infectious Diseases, 2003
- Intussusception among Infants Given an Oral Rotavirus VaccineNew England Journal of Medicine, 2001
- Current status and future priorities for rotavirus vaccine development, evaluation and implementation in developing countries1Prepared as a review for the Consensus Workshop on Rotavirus Vaccines for use in Developing Countries, Geneva, January 9–10, 1997. Sponsored by: The Global Programme for Vaccines, World Health Organization, The Children's Vaccine Initiative and the Centers for Disease Control and Prevention.1Vaccine, 1999
- Randomised placebo-controlled trial of rhesus-human reassortant rotavirus vaccine for prevention of severe rotavirus gastroenteritisThe Lancet, 1997